Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients

被引:0
作者
El-Zayadi, A
Selim, O
Haddad, S
Simmonds, P
Hamdy, H
Badran, HM
Shawky, S
机构
[1] Ain Shams Univ, Hepatol Dept, Cairo, Egypt
[2] Univ Edinburgh, Dept Microbiol, Edinburgh EH8 9YL, Midlothian, Scotland
[3] Menoufia Univ, Liver Inst, Menoufia, Egypt
[4] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia
来源
ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 1999年 / 31卷 / 06期
关键词
chronic hepatitis C; combination therapy; interferon; ribavirin;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim. Treatment of chronic hepatitis C patients, infected with genotype 4 with interferon-alpha yielded a limited response. Our aim was to compare the efficacy of inteferon-alpha alone and in combination with ribavirin in chronic hepatitis C patients infected with genotype 4. Patients, Fifty-two chronic hepatitis C patients (all males) infected with genotype 4, who had not received interferon, were randomized into 2 equal comparable groups. Methods, Group I received interferon alpha-2b "Schering Plough" 3 MU, tiw combined with ribavirin (1000 mg/day). Group II received interferon alpha-2b alone in the same dose. Both groups were evaluated monthly, at the end of 24 weeks of treatment and 24 weeks later Two patients were dropped from group I and one patient from group II. Results, Biochemical response: at the end of treatment, a rerum to normal of ALT was obtained in 16/24 (66.7%) patients on combination therapy vs 8/25 (32%) patients on interferon alone (p = 0.0152). At the end of follow-up, a sustained response was achieved in 10/24 (41.7%) patients on combination therapy vs 4/25 (16%) patients on interferon (p = 0.0468). Virologic response: at the end of treatment, the rates of virological response were higher in the patients on combination therapy 9/24 (37.5%) than in those on interferon 4/25 (16%) (p = 0.0380). At the end of follow-up, loss of serum HCV RNA was reported in 5/24 (20.8%) patients on combination therapy vs 2/25 (8%) patients on interferon (p = 0.1916). Histologic response: mild histologic improvement was shown by a decrease in the inflammatory score, which was hightest in patients in the combination group. Conclusions. In chronic hepatitis C patients infected with genotype 4 combination therapy with interferon-alpha and ribavirin was more effective than treatment with interferon monotherapy. At the end of the follow-up, about 50% of patients in both groups were still viraemic though their ALT remained normal.
引用
收藏
页码:472 / 475
页数:4
相关论文
共 19 条
  • [1] Hepatitis C antibody prevalence in blood donors in different governorates in Egypt
    Arthur, RR
    Hassan, NF
    Abdallah, MY
    ElSharkawy, MS
    Saad, MD
    Hackbart, BG
    Imam, IZ
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1997, 91 (03) : 271 - 274
  • [2] ARTHUR RR, 1996, MED COMM, V67, P4
  • [3] A HIGH-RISK OF HEPATITIS-C INFECTION AMONG EGYPTIAN BLOOD-DONORS - THE ROLE OF PARENTERAL DRUG-ABUSE
    BASSILY, S
    HYAMS, KC
    FOUAD, RA
    SAMAAN, MD
    HIBBS, RG
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1995, 52 (06) : 503 - 505
  • [4] CHEMELLO L, 1995, SCAND J INFECT DIS, V27, P325
  • [5] SURVEY OF MAJOR GENOTYPES AND SUBTYPES OF HEPATITIS-C VIRUS USING RFLP OF SEQUENCES AMPLIFIED FROM THE 5' NONCODING REGION
    DAVIDSON, F
    SIMMONDS, P
    FERGUSON, JC
    JARVIS, LM
    DOW, BC
    FOLLETT, EAC
    SEED, CRG
    KRUSIUS, T
    LIN, C
    MEDGYESI, GA
    KIYOKAWA, H
    OLIM, G
    DURAISAMY, G
    CUYPERS, T
    SAEED, AA
    TEO, D
    CONRADIE, J
    KEW, MC
    LIN, M
    NUCHAPRAYOON, C
    NDIMBIE, OK
    YAP, PL
    [J]. JOURNAL OF GENERAL VIROLOGY, 1995, 76 : 1197 - 1204
  • [6] Factors predictive of a beneficial response to therapy of hepatitis C
    Davis, GL
    Lau, JYN
    [J]. HEPATOLOGY, 1997, 26 (03) : S122 - S127
  • [7] Side effects of alpha interferon in chronic hepatitis C
    Dusheiko, G
    [J]. HEPATOLOGY, 1997, 26 (03) : S112 - S121
  • [8] Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
    Dusheiko, G
    Main, J
    Thomas, H
    Reichard, O
    Lee, C
    Dhillon, A
    Rassam, S
    Fryden, A
    Reesink, H
    Bassendine, M
    Norkrans, G
    Cuypers, T
    Lelie, N
    Telfer, P
    Watson, J
    Weegink, C
    Sillikens, P
    Weiland, O
    [J]. JOURNAL OF HEPATOLOGY, 1996, 25 (05) : 591 - 598
  • [9] Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4
    ElZayadi, A
    Simmonds, P
    Dabbous, H
    Prescott, L
    Selim, O
    Ahdy, A
    [J]. JOURNAL OF VIRAL HEPATITIS, 1996, 3 (05) : 261 - 264
  • [10] ANALYSIS OF CLINICAL AND VIROLOGICAL FACTORS ASSOCIATED WITH RESPONSE TO ALPHA-INTERFERON THERAPY IN CHRONIC HEPATITIS-C
    GARSON, JA
    BRILLANTI, S
    WHITBY, K
    FOLI, M
    DEAVILLE, R
    MASCI, C
    MIGLIOLI, M
    BARBARA, L
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1995, 45 (03) : 348 - 353